Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Michel Delforge; Roman Hájek; Heinz Ludwig; Thierry Façon; Jesús F. San Miguel; Hermann Einsele; Philippe Moreau; Pieter Sonneveld; Mario Boccadoro; Gordon Cook; Ma Victoria Mateos; Hareth Nahi; Hartmut Goldschmidt; Meletios A Dimopoulos; Paulo Lúcio; Joan Bladé

doi:10.3324/haematol.2019.224204

Abstract

1 min read

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

Related publications

Article2021

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, Mattia D’Agostino, Luis Gerardo Rodríguez‐Lobato, Sophia Danhof, Nico Gagelmann, Nicolaus Kröger, Rakesh Popat, Niels W.C.J. van de Donk, Evangelos Terpos, Meletios A Dimopoulos, Pieter Sonneveld, Hermann Einsele, Mario Boccadoro

Article2025

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

Niels W.C.J. van de Donk, Philippe Moreau, Jesús F. San Miguel, María‐Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksaç, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L.B.M. Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hájek, Jelena Bila, Güldane Cengiz Seval, Michael O’Dwyer, Heinz Ludwig, Carlos Fernández de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodríguez‐Otero, Kwee Yong, ,

Article2022

PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

N. Munshi, A. Spencer, M. S. Raab, Aisha Masood, M. Martinez-Prieto, Junjun Chu, Syouzou IIDA, S. Lonial, Meletios A Dimopoulos

Article2025

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell

Maria Gavriatopoulou, Sotirios Manganas, Ioannis Ntanasis‐Stathopoulos, Meletios A Dimopoulos

Article2021

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead

Tahereh Soltantoyeh, Behnia Akbari, Amirali Karimi, Ghanbar Mahmoodi Chalbatani, Navid Ghahri-Saremi, Jamshid Hadjati, Michael R Hamblin, Hamid Reza Mirzaei